| (Values in U.S. Thousands) | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 2,630 | 6,650 | 8,970 | 7,510 | 0 |
| Sales Growth | -60.45% | -25.86% | +19.44% | unch | unch |
| Net Income | -23,420 | -14,230 | -12,600 | -5,790 | -9,240 |
| Net Income Growth | -64.58% | -12.94% | -117.62% | +37.34% | +35.20% |
Gelesis Holdings Inc (GLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Fiscal Year End Date: 12/31